Haloperidol is commonly used in the ICU, and, at increasingly lower doses, to treat and prevent agitation and delirium [1]. Rate-corrected QT-interval (QTc) prolongation, a well-established risk factor for torsades de pointes (TdP), frequently occurs in the critically ill [2]. Current product labeling for IV haloperidol includes a warning for QTc prolongation and TdP, and all hospital medication systems are programmed to detect drug interactions that might prolong the QTc. Therefore, ICU clinicians remain vigilant in addressing this cardiovascular risk when making haloperidol prescribing decisions and routinely monitoring the QTc after haloperidol has been initiated. While IV haloperidol has been associated with QTc prolongation in retrospective studies when administered at a high daily dose (≥20 mg) [3, 4], the association between lower-dose IV haloperidol and QTc prolongation remains unclear.
(≥500 ms and/or an increase ≥60 ms above baseline not attributable to the use of non-haloperidol QTc prolonging medications) occurred [5] . Patients with potential underlying risk factors for QTc prolongation were not excluded. The QTc was evaluated every 12 h by a telemetry strip and confirmed with a 12-lead ECG if prolongation was detected.
Both the baseline QTc (430 ± 32 ms H vs. 421 ± 39 ms P, p = 0.26) and average maximum QTc over the course of the study (457 ± 40 ms H vs. 466 ± 39 ms P, p = 0.34) were similar between the two groups. The average rate of change over time of the QTc was similar between groups (−0.16 ms/h H vs. −0.11 ms/h P, p = 0.70) (Fig. 1) . Between groups, the difference in the proportion of patients who developed QTc prolongation [8/34 (24 %) H vs. 14/34 (41 %) P, p = 0.19], a QTc ≥500 ms alone [4/34 (12 %) H vs. 3/34 (9 %) P, p = 1.00], or an increase in the QTc ≥60 ms alone [6/34 (18 %) H vs. 14/34 (41 %) P, p = 0.063] were similar. A log-rank test comparing Kaplan-Meier curves revealed the percentage of H-and P-group patients free of QTc prolongation was similar across all study days (p = 0.33).
Using a rigorous study design and including patients with potential underlying non-H-related risk factors for QTc prolongation, we report that the use of low-dose IV haloperidol in a mixed population of critically ill adults is not associated with QTc prolongation. Our results, while requiring confirmation in larger cohorts and in patients receiving slightly higher daily IV haloperidol doses (e.g., 8 mg), suggest that additional QTc monitoring may not *Correspondence: j.devlin@neu.edu 1 School of Pharmacy, Northeastern University, 360 Huntington Ave, TF R218, Boston, MA 02115, USA Full author information is available at the end of the article be required after low-dose IV haloperidol is initiated in the ICU.
